Clinical bottom line
Myopic macular degeneration (MMD) remains a leading cause of vision loss in high myopia, with limited effective treatments historically available. Emerging therapies, including intravitreal biologics such as panitumumab targeting vascular endothelial growth factor (VEGF) pathways, and novel anti-inflammatory strategies, show promise in slowing progression and improving visual outcomes. Advances in understanding the inflammatory and immune mechanisms underlying MMD have opened avenues for targeted interventions. However, current evidence is preliminary, and long-term safety and efficacy data are needed before widespread adoption (Bikbov et al., 2024; Zhang et al., 2025; Sankaridurg et al., 2021).
What the evidence shows
Bikbov et al. (2024) report on intravitreal panitumumab, a monoclonal antibody against VEGF, demonstrating potential to reduce neovascularization and macular atrophy in MMD patients. Early-phase clinical data suggest improved anatomical and functional outcomes compared to historical controls.
Zhang et al. (2025) provide a comprehensive review of inflammation and immune pathways implicated in myopia and MMD, highlighting cytokines and cellular mediators as therapeutic targets. They discuss experimental agents modulating these pathways, which may complement anti-VEGF treatments.
Sankaridurg et al. (2021), through the International Myopia Institute (IMI), emphasize the global impact of myopia and MMD, advocating for integrated strategies combining prevention, early detection, and emerging treatments to mitigate disease burden.
Hubschman et al. (2009) offer foundational insights into experimental and emerging treatments for macular degeneration, including surgical and pharmacologic approaches, some of which may be adapted for MMD.
Ning et al. (2025) discuss artificial intelligence applications in ophthalmology, which may enhance diagnosis, monitoring, and personalized treatment planning for MMD.
Caveats and uncertainty
Most emerging treatments for MMD are in early clinical or experimental stages, with limited large-scale randomized controlled trials.
Long-term safety, especially regarding repeated intravitreal injections and immunomodulatory agents, remains to be established.
Heterogeneity in MMD pathology and patient characteristics complicates treatment standardization.
Surgical interventions have limited applicability and carry risks that may outweigh benefits in many cases.
Cost and accessibility of novel biologics and technologies may limit widespread use.
How this may change practice
Clinicians should remain informed about evolving therapeutic options for MMD, particularly intravitreal biologics targeting VEGF and inflammatory pathways.
Integration of multimodal imaging and AI tools may improve early detection and monitoring, facilitating timely intervention.
Personalized treatment plans considering disease stage, patient risk factors, and comorbidities will optimize outcomes.
Collaboration with retina specialists and participation in clinical trials can provide patients access to cutting-edge therapies.
Ongoing research and guideline updates will refine indications and protocols for emerging treatments.